Roberto Bordonaro

4.9k citations
139 papers · 3.5k · 1 hit paper · h-index 31

Impact in

  • Oncology top 1%
    • Colorectal Cancer Treatments and Studies
    • Pancreatic and Hepatic Oncology Research
    • Cancer Immunotherapy and Biomarkers
    • Cancer Genomics and Diagnostics

Papers in

    • Colorectal Cancer Treatments and Studies 53
    • HER2/EGFR in Cancer Research 6
    • Lung Cancer Diagnosis and Treatment 8
    • Gastric Cancer Management and Outcomes 7
    • Lung Cancer Treatments and Mutations 6

Roberto Bordonaro

134 papers receiving 3.4k citations

Roberto Bordonaro's Hit Papers

Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial 2017 · 339 citations
3390+3+6Years since publication100200300

Peers

Roberto Bordonaro
Comparison fields: 5 of 89
  • Oncology 1.6k
  • Cancer Research 356
  • Pulmonary and Respiratory Medicine 575
  • Pathology and Forensic Medicine 274
  • Geriatrics and Gerontology 55
Replace Ioannis Boukovinas with:
Ioannis Boukovinas Greece
Richard William Gregg Canada
Antonio Frassoldati Italy
Nevin Murray Canada
G. Deplanque France
Kilian Elizabeth Salerno United States
Manish R. Sharma United States
Antonio Calles Spain
Yusuke Okuma Japan
Roberto Ferrara Italy
Roberto Bordonaro relative to Ioannis Boukovinas Greece Ioannis Boukovinas's profile →
Citations per field
00.5×1.5×2.2×
Ioannis Boukovinas · 1×
Citations per year

Countries citing papers authored by Roberto Bordonaro

Since Specialization
Citations

This map shows the geographic impact of Roberto Bordonaro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roberto Bordonaro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roberto Bordonaro more than expected).

Fields of papers citing papers by Roberto Bordonaro

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roberto Bordonaro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roberto Bordonaro. The network helps show where Roberto Bordonaro may publish in the future.

Co-authors

The 25 scholars most cited alongside Roberto Bordonaro, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Roberto Bordonaro Line = papers co-authored together Roberto Bordonaro links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 139 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial
Hit paper breakdown →
2017339
2 2020261
3 2005237
4 2005138
5 2015125
6 2007119
7 2004100
8 2014100
9 201799
10 201479
11 201679
12 200564
13 202261
14 202056
15 202354
16 201852
17 202349
18 200747
19 200646
20 201744

About Roberto Bordonaro

Roberto Bordonaro is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Pathology and Forensic Medicine and Economics and Econometrics, having authored 139 papers that have together received 3.5k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (53 papers), Lung Cancer Diagnosis and Treatment (8 papers), Lymphoma Diagnosis and Treatment (8 papers), Gastric Cancer Management and Outcomes (7 papers), Lung Cancer Treatments and Mutations (6 papers), Breast Cancer Treatment Studies (6 papers), HER2/EGFR in Cancer Research (6 papers) and Health Systems, Economic Evaluations, Quality of Life (5 papers). The work is most often cited by research in Oncology (1.6k citations), Cancer Research (356 citations), Pulmonary and Respiratory Medicine (575 citations), Pathology and Forensic Medicine (274 citations) and Geriatrics and Gerontology (55 citations). Roberto Bordonaro has collaborated with scholars based in Italy, United Kingdom and France. Frequent co-authors include Stefano Sergio Cordio, Michele Reni, Massimo Libra, Luca Falzone, Caterina Cecilia Stelitano, Eugenio Villa, Carlo Milandri, Evaristo Maiello, Paolo Passoni and Elisa Bonetto. Their work appears in journals such as Annals of Oncology, ESMO Open, Journal of Clinical Oncology, European Journal of Cancer and Cancers.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact